Effective T-cell therapy against cancer is dependent on the formation of long-lived, stem cell–
like T cells with the ability to self-renew and differentiate into potent effector cells. Here, we …

Adoptive T cell therapy has shown clinical potential for patients with cancer, though effective
treatment is dependent on longevity and potency of the exploited tumor-reactive T cells …

The CD8+ T-cell response comprises terminally differentiated effector cells and antigen-
experienced memory T cells. The latter encompass central (TCM) and effector (TEM) …

Background Insufficient persistence and effector function of chimeric antigen receptor (CAR)-
redirected T cells have been challenging issues for adoptive T cell therapy. Generating …

Adoptive cell therapy is a potentially curative therapeutic approach for patients with cancer.
In this treatment modality, antitumor T cells are exponentially expanded in vitro prior to …

T cell-based adoptive cell therapy (ACT) has exhibited excellent antitumoral efficacy
exemplified by the clinical breakthrough of chimeric antigen receptor therapy (CAR-T) in …

Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …

Adoptive T-cell immunotherapy has garnered wide attention, but its effective use is limited by
the need of multiple ex vivo manipulations and infusions that are complex and expensive. In …

Adoptive immunotherapy can induce sustained therapeutic effects in some cancers.
Antitumor T-cell grafts are often individually prepared in vitro from autologous T cells, which …

Generating stem-like memory T cells (TSCM) is a potential strategy to improve adoptive
immunotherapy. Elucidating optimal ways to modulate signaling pathways that enrich TSCM …